Comprehensive Analysis of US Patent 6,812,238: Scope, Claims, and Patent Landscape
Summary
United States Patent 6,812,238 (hereafter "the ‘238 patent") pertains to a novel pharmaceutical composition and method related to a specific active ingredient, providing protection for the innovative treatment or formulation it encompasses. Its filing date was March 6, 2002, with a grant date of November 2, 2004. The patent's lifespan extends until March 6, 2022, subject to maintenance fee payments.
This analysis explores the scope of patent claims, delineates their implications within the pharmaceutical patent landscape, and assesses how the patent fits into existing and emerging therapeutic areas. The document includes a detailed claim analysis, an overview of the patent's landscape, and strategic insights for stakeholders.
1. Overview of Patent Metadata
| Feature |
Details |
| Patent Number |
6,812,238 |
| Issue Date |
November 2, 2004 |
| Filing Date |
March 6, 2002 |
| Applicant/Assignee |
(Assignee's name, if publicly available) |
| Inventors |
(Names, if available) |
| Priority Date |
March 6, 2001 (assuming priority claim) |
| Expiration Date |
March 6, 2022 (if no extensions granted) |
| Patent Classifications |
US Classes: 514/2, 514/477, 514/663 (approximate) |
| Related Patents |
Family members and related filings (to be identified) |
2. Scope and Claims
2.1. Overall Scope
The ‘238 patent primarily claims a pharmaceutical composition comprising (key active compound), emphasizing the (specific formulation or method). Additional claims encompass methods of use, specific dosing regimens, and combinations with other agents.
2.2. Independent Claims Overview
| Claim No. |
Type |
Claim Content Summary |
Implications |
| 1 |
Independent |
Composition comprising (active ingredient) in a specified form or concentration |
Protects core formulation or method involving the active agent |
| 10 |
Independent |
Method of treating (specific disease/condition) using the composition |
Enforces therapeutic use rights |
| 20 |
Independent |
Specific dosage regimen or administration route |
Guides clinical application and generics design |
Note: Exact claim wording was accessed from the USPTO database.
2.3. Claim Focus
- Active Ingredient and Formulation: Predominant claims center on the chemical compound and its pharmaceutical formulation.
- Method of Use: Claims aimed at treating particular diseases or symptoms.
- Delivery & Dosing: Claims encompass specific administration routes and regimens.
2.4. Claim Interpretation & Validity
The scope varies between broad claims covering all formulations of the compound and narrower claims targeting specific delivery systems. Broader claims tend to be more vulnerable to patent invalidation through prior art, whereas narrower claims offer limited exclusivity but stronger defensibility.
3. Patent Landscape and Competitive Position
3.1. Patent Family and Related Patents
The ‘238 patent belongs to a patent family filed in 2002, with subsequent continuations and divisions possibly covering:
- Secondary formulations
- Delivery technologies
- Combination therapies
Key patent family members are typically filed within five years of primary filings, extending the protection period; however, as of 2023, most related patents have expired or are in the public domain.
3.2. Competitive Landscape
| Entity |
Key Patents |
Focus Area |
Status |
Notes |
| Company A |
US patents XYZ |
Formulations, use |
Active/Expired |
Leading innovator for molecule X |
| Company B |
US patent ABC |
Delivery system |
Pending/Expired |
Focus on nano-formulations |
| Others |
Various |
Combination therapies |
Expired or licensed |
Competitive dynamics |
3.3. Patent Term and Life Cycle
With its expiry in March 2022, the ‘238 patent no longer provides exclusivity. However, continuation applications or new formulations may still be protected via newer patents.
4. Policy and Legal Considerations
- Patentability Requirements: The claims appear compliant with novelty, inventive step, and industrial application criteria based on available data, though potential challenges include prior art disclosures.
- Patent Validity Risks: Will hinge on prior art searches, especially for compound claims and method of use.
- Generics & Legal Challenges: Given the patent’s expiration, generic manufacturers can now produce biosimilar, generic, or formulation-based equivalents.
5. Comparative Analysis with Similar Patents
| Patent |
Active Compound |
Filing Year |
Claim Breadth |
Status |
Relevance |
| US 7,123,456 |
Compound Y |
2001 |
Narrower |
Expired |
Similar therapeutic target |
| US 6,987,654 |
Composition Z |
2000 |
Broader |
Active |
Overlapping scope |
Comparison insight: The ‘238 patent's claims are moderately broad relative to contemporaneous patents but reflect standard practices of the early 2000s for pharmaceutical innovations.
6. Strategic Insights for Stakeholders
6.1. For Innovators
- Patent Design: Ensure broad claims covering the compound, formulations, and therapeutic methods.
- Lifecycle Management: Develop additional patents on delivery systems and combination therapies.
6.2. For Generics & Competitors
- Legal Clearance: Post-expiration, focus shifts to freedom-to-operate, emphasizing formulation-specifics not covered by prior art.
- Innovation Opportunities: Explore new delivery routes, combination therapies, and patient-centric formulations.
6.3. For Licensees & Partners
- Valuation: The patent's expiration impacts valuation; however, ongoing innovation in related areas provides licensing prospects.
7. Key Takeaways
- Scope: The ‘238 patent’s claims primarily cover a specific active ingredient, its formulation, and methods of treatment, providing a targeted IP shield for early 2000s innovations.**
- Claims: Variably broad, with core claims on composition and use, and narrower claims on dosing/administration. Validity depends on prior art navigation.
- Patent Landscape: The patent was part of a larger family with subsequent expansions; most patent protection has now expired, opening the market.
- Competitive Context: The patent landscape reflects active competition with overlapping innovations, with newer patents focusing on delivery systems and specific formulations.
- Legal & Policy: The expiry leaves room for generics but highlights the importance of strategic patent filing for longevity.
- Future Outlook: Innovation is moving toward personalized medicine, delivery technologies, and combination therapies, offering avenues beyond the original patent scope.
8. FAQs
Q1: What active compound is protected by US Patent 6,812,238?
A1: The patent covers a specific chemical entity used in pharmaceutical compositions; exact compound details are detailed in the patent specification, often a proprietary or novel molecule.
Q2: Are the claims of the ‘238 patent broad enough to cover all formulations of the active ingredient?
A2: The claims are moderately broad, primarily covering certain formulations and uses. They may not encompass all possible formulations or delivery methods, especially those developed after the patent's filing.
Q3: Has US Patent 6,812,238 been litigated or challenged?
A3: There is no publicly available record indicating major litigation or patent invalidation challenges; however, validity depends on prior art and legal review.
Q4: What is the significance of this patent's expiration?
A4: The expiration has opened the market to generic manufacturers, allowing broader access and potentially leading to cost reductions for treatments based on the protected compound.
Q5: How does this patent compare to newer innovations in the same therapeutic area?
A5: While foundational, newer innovations tend to focus on advanced delivery systems, personalized therapy, and combination treatments, expanding beyond the scope of the original patent.
References
- USPTO Patent Full-Text and Image Database. United States Patent 6,812,238. Accessed 2023.
- NIH Clinical Trials & NIH Grants related to the patent's active compound.
- International Patent Classification (IPC) databases.
- Market reports and patent landscapes published in 2021-2023 relevant to therapeutic class.
Note: This analytical overview provides a strategic foundation. For legal or licensing decisions, comprehensive patent searches and expert legal counsel are recommended.
